Emerging Treatment Paradigms for Advanced Lung Cancer

home / peer-exchange / advanced-lung-cancer-emerging-treatment
Impact of PACIFIC Trial on Locally Advanced NSCLC

EP. 1: Impact of PACIFIC Trial on Locally Advanced NSCLC

February 26th 2019
The Role of Surgery in NSCLC Following PACIFIC Trial

EP. 2: The Role of Surgery in NSCLC Following PACIFIC Trial

February 26th 2019
Imaging Schedule Following CRT in Locally Advanced NSCLC

EP. 3: Imaging Schedule Following CRT in Locally Advanced NSCLC

February 26th 2019
Biomarker Testing in Stage III NSCLC

EP. 4: Biomarker Testing in Stage III NSCLC

February 26th 2019
Driver Mutations Trump PD-L1 Expression in Lung Adenocarcinoma

EP. 5: Driver Mutations Trump PD-L1 Expression in Lung Adenocarcinoma

February 26th 2019
Choosing Therapy for Newly Diagnosed NonDriver NSCLC

EP. 6: Choosing Therapy for Newly Diagnosed NonDriver NSCLC

February 26th 2019
Looking at the IMpower Data in NSCLC

EP. 7: Looking at the IMpower Data in NSCLC

February 26th 2019
CheckMate-227 and the Role of TMB in NSCLC

EP. 8: CheckMate-227 and the Role of TMB in NSCLC

February 26th 2019
Treatment Options for mNSCLC After Progression

EP. 9: Treatment Options for mNSCLC After Progression

February 26th 2019
A Win for Small-Cell Lung Cancer: IMPOWER 133

EP. 10: A Win for Small-Cell Lung Cancer: IMPOWER 133

February 26th 2019
ADRIATIC Trial in Locally Advanced Small-Cell Lung Cancer

EP. 11: ADRIATIC Trial in Locally Advanced Small-Cell Lung Cancer

February 26th 2019
Molecular Testing for NSCLC in 2019

EP. 12: Molecular Testing for NSCLC in 2019

February 26th 2019
Osimertinib, the Standard for EGFR+ NSCLC

EP. 13: Osimertinib, the Standard for EGFR+ NSCLC

February 26th 2019
Resistance Mechanisms in EGFR+ NSCLC

EP. 14: Resistance Mechanisms in EGFR+ NSCLC

February 26th 2019
Available Therapies for ALK-Rearranged NSCLC

EP. 15: Available Therapies for ALK-Rearranged NSCLC

February 26th 2019
A Game-Changing Year for NSCLC

EP. 16: A Game-Changing Year for NSCLC

February 26th 2019